To restrict postmarketing surveillance to a ''Potential risk: to be quantified in large-scale studies'' [1] is unusual as it excludes routine pharmacovigilance, no matter how limited that may be perceived. My study [2] showed that a lessdismissive attitude to Sub-Saharan pharmacovigilance is warranted.
It appears that until late 2011, Sanofi did not give weight to the published Anglophone (from 1976) and Francophone (2004) case reports referenced in my paper associating extrapyramidal reactions with amodiaquine and the repeated advice (2010 and 2011) of the WHO's Advisory Committee on Safety of Medicinal Products (ACSoMP) that reporting to the Uppsala Monitoring Centre supported a clear association with artesunate amodiaquine combination products [3, 4] . These followed progress reports to ACSoMP of my ongoing analysis. ACSoMP recommended that the details be published and shared with the manufacturer for a possible update of the Summary of Product Characteristics [3] .
It is unclear whether any of the notifications mentioned by Dr Bompart [5] that led to Sanofi's acceptance of the association came from the large-scale studies. If some did, details should be published and an estimate of incidence disclosed.
